Navigation Links
BioSoteria CEO to Present at Drug Safety Conference
Date:11/18/2009

BioSoteria announced that its President and CEO Sally Van Doren, PharmD, will present at the 9th DIA Conference for Contemporary Pharmacovigilance and Risk Management Strategies, which takes place January 10-13, 2010, in Washington, DC. Dr. Van Doren will present on the topic of the Integrated Summary of Safety.

Emeryville, CA (PRWEB) November 18, 2009 -- BioSoteria, Inc., a drug safety service provider and training company, announced today that its President and Chief Executive Officer Sally Van Doren, PharmD, will present at the 9th Drug Information Association (DIA) Conference for Contemporary Pharmacovigilance and Risk Management Strategies. The meeting will take place January 10-13, 2010, in Washington, DC.

Dr. Van Doren will present on the topic of the Integrated Summary of Safety (ISS) during the session regarding Safety Reporting for Drugs and Biologics. Her talk will focus on the practical aspects of authoring the ISS, such as project planning, data pooling decisions, and integration points with the Common Technical Document and the product label.

"After authoring numerous safety analyses over the years, I have learned that the ISS is not as straight-forward as it appears in content requirements," said Dr. Van Doren. "I look forward to sharing my experience with this audience of drug safety professionals."

The DIA Conference for Contemporary Pharmacovigilance and Risk Management has become an important annual meeting for drug safety practitioners. The three-day program addresses regulatory activities and the complexities involved in maximizing the benefits and minimizing the risks of pharmaceuticals throughout all phases of development and marketed use. For more information, please visit the DIA website at www.diahome.org.

About Sally Van Doren, PharmD
Dr. Van Doren is the President, Chief Executive Officer and Founder of BioSoteria, the fastest-growing drug safety service provider and training company based on the West Coast. With more than twenty years of pharmaceutical industry experience, Dr. Van Doren has held leadership positions in drug safety and risk management, clinical development, and medical information services. She has been directly involved in numerous safety analyses for US and European product marketing applications and has advised many companies on a broad range of safety issues.

About BioSoteria, Inc.
BioSoteria is an innovative drug safety services and education provider to the biopharmaceutical industry. BioSoteria offers a wide range of consulting and operational services in clinical safety, postmarketing pharmacovigilance, and pharmaceutical risk management. To learn more about BioSoteria, please visit the company's website or call toll-free at 1-866-660-5553, extension 010.

###

Read the full story at http://www.prweb.com/releases/pharmacovigilance/conference/prweb3225234.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. BioSoteria Drug Safety Newsletter Reaches Milestone
2. BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification
3. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
4. Avicena Group to Present at Noble Financial Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CEL-SCI to Present at the Noble Financial Conference
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Strategic Diagnostics Updates Roth Conference Presentation Time
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
BioSoteria CEO to Present at Drug Safety Conference
(Date:12/6/2016)... ... December 06, 2016 , ... The Osteoarthritis Research Society International ... Administration (FDA) to consider OA as a serious disease. As an organization of ... population of OA patients, many of whom may experience progressive disability and decreased ...
(Date:12/6/2016)... , ... December 06, 2016 ... ... Great Point Partners ("GPP") portfolio company, today announced it has acquired the ... a subsidiary of Chiltern International and focuses on clinical trial drug packaging, ...
(Date:12/6/2016)... Calif. , Dec. 6, 2016  SRI ... to $150 million from the National Institutes of ... and the Division of AIDS (NIAID-DAIDS) to support ... other non-vaccine pre-exposure (PreP) agents. Under the seven-year ... preclinical product development services for candidate HIV-prevention products ...
(Date:12/5/2016)... , Dec. 5, 2016 Axovant Sciences ... biopharmaceutical company focused on the treatment of dementia, today ... for the treatment of Alzheimer,s disease will be presented ... Meeting on Friday, December 9, 2016 in ... show results of both simple and complex measures of ...
Breaking Biology Technology:
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... 30, 2016 Not many of us realize that we spend ? of ... we need to do it well. Inadequate sleep levels have been found to lead ... diabetes, and even cancer. Maybe now is the best time to rethink ... them to manage their sleep quality? Continue Reading ... ...
Breaking Biology News(10 mins):